Based on what pruden states this doesn't sound like a fit for Titan with the jnj/Google deal:
Gary Pruden - Worldwide Chairman, Medical Devices
Thanks, Bob. So in terms of robotics, listen, I will leave the announcement to the new co of the company. They have some announcements that will be coming out in the next few weeks, so I'd like to leave the leader there to do it.
As mentioned this is a partnership between ourselves and my partner, Andy Conrad at Google Life Sciences, so new company will make that announcement. In terms of the development stage, yes, we were in the phase where we are integrating right, our technology with the Google technology, right, in terms of from a systems engineering perspective, integrating informatics into the design of our robot.
So we are looking, I would say you're on the earlier side of your range, right. I would say it's the next couple years. We'd obviously like to accelerate that, but we want to make sure that we stay true to our value proposition, which is we think what's available today is really the model that's more like the mainframe computer 50 years ago.
We intend to go to the iPad version and that's what we want to launch. With a more integrated informatics diagnostics, right, that are available for the surgeon around the world as a lower cost to serve.
So we think that it's better to do it right. There will be a lot of follow-on competitors that come in the next couple years that I think will be more big box players. That is clearly not our strategy.
And we think this is an opportunity to be disruptive in a very unique partnership to create value for our customers, patients and also for the Johnson & Johnson shareholders.
News 
Market Data 
Discover 
